靶向 TNF-α/IL-23/IL-17 轴的生物制剂在银屑病和银屑病关节炎中的疗效差异。

Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.

机构信息

Department of Dermatology, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan.

Department of Dermatology, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan; Division of Skin Surface Sensing, Department of Dermatology, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan; Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan.

出版信息

Cytokine. 2018 Nov;111:182-188. doi: 10.1016/j.cyto.2018.08.025. Epub 2018 Aug 29.

DOI:10.1016/j.cyto.2018.08.025

PMID:30172115

Abstract

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.

摘要

银屑病和银屑病关节炎给患者带来了显著的身心负担。一个加速的 TNF-α/IL-23/IL-17 轴是其主要的发病机制；因此，抗 TNF-α/IL-23/IL-17 生物制剂对银屑病和银屑病关节炎的皮肤和关节病变的治疗非常有效。鉴于在银屑病关节炎中，IL-17 特征在皮肤中的上调程度高于滑膜，抗 IL-23/IL-17 药物在治疗皮肤病变方面似乎优于抗 TNF-α药物。在这篇综述中，我们重点关注抗 TNF-α/IL-23/IL-17 生物制剂在银屑病和银屑病关节炎中的疗效差异。